Artículos del autor

solaci

Day 2

BIOSS: results of the new drug-eluting stent for bifurcations

This new device is a stainless steel platform of 120 µm thick with a sirolimus-eluting bio-absorbable polymer....
solaci -
Day 2

DEMONSTR8: better endothelial coverage by OCT for the new DES

There is still concern about the safety of drug-eluting stents (DES) due to the possibility of late...
solaci -
Day 3

TRANSLATE-POPS: Routine measurement of platelet aggregation generates a minimal impact on the treatment setting

The high platelet reactivity is associated with adverse events after stent implantation. Current guidelines consider the measurement...
solaci -
Day 1

BIOFLOW II. Stent eluidor de sirolimus com polímero degradável.

This non-inferiority design study compared the sirolimus-eluting stent with biodegradable polymer versus everolimus-eluting stent with permanent polymer...
solaci -
Day 1

SYNTAX II: multiple vessels using iFR / FFR and IVUS

This study is still in progress and includes patients using SYNTAX II score based on functional invasive...
solaci -
Day 1

EUROMAX: Bivalirudin during transport to primary angioplasty

The HORIZONS AMI trial showed the usefulness of bivalirudin in reducing mortality and bleeding compared with the...
solaci -
Day 1

DESolveNx trial: Results of the new bioabsorbable platform

This new device consists of a novolimus releasing bioabsorbable polylactic acid platform that in vitro studies has...
solaci -
Day 3

MOZART: IVUS reduces contrast volume needed for angioplasty

Contrast nephropathy is associated with increased morbidity and so this study evaluates the possibility of reducing the...
solaci -